Inicio › Cáncer de seno › Nevada
Ensayos clínicos de Cáncer de seno en Nevada
22 estudios sobre Cáncer de seno buscan participantes en Nevada.
Ciudades en Nevada
Texto oficial del estudio (inglés)
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Renown Regional Medical Centre, Reno
- Cancer Care Specialists, Reno
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT05696626A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
- Renown Health Conrad Breast Center at South Meadows, Reno
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 12 nov 2026 · NCT07541079A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Optum Care Cancer Center ( Site 0050), Las Vegas
- Renown Regional Medical Center ( Site 0041), Reno
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06966700A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Renown Regional Medical Center, Reno
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT03424005A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07029399Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Renown Health Medical Oncology, Reno
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06982521E-Mindfulness Approaches for Living After Breast Cancer
- Renown Regional Medical Center, Reno
ReclutandoFase 3
Edades de 18 a 50 · Todos los sexos · Actualizado el 4 nov 2026 · NCT06748222Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- y 24 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06418204Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- y 24 más
ReclutandoFase 3
Edades de 18 a 60 · Mujeres · Actualizado el 4 nov 2026 · NCT05879926A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Cancer Care Specialists ( Site 9503), Reno
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07060807A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Reno
ReclutandoFase 3
Edades de 18 a 130 · Todos los sexos · Actualizado el 19 oct 2026 · NCT07647328A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Las Vegas
- y 9 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT07062965T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
- Comprehensive Cancer Centers of Nevada, Las Vegas
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 oct 2026 · NCT07683754A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Cancer Care Specialists, Reno
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06369285Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Specialist of Reno, Reno
ReclutandoEstudio observacional
Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07211178A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Comprehensive Cancer Centers of Nevada, Las Vegas
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06764940Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Comprehensive Cancer Centers of Nevada, Henderson
ReclutandoFase 3
Edades de 18 a 100 · Todos los sexos · Actualizado el 6 ago 2026 · NCT05232916A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT05377996De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
- Radiation Oncology Centers of Nevada Central, Las Vegas
- y 8 más
ReclutandoFase 3
Edades de 50 a 70 · Todos los sexos · Actualizado el 23 abr 2026 · NCT04852887A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
ReclutandoFase 1
Edades de 18 en adelante · Mujeres · Actualizado el 22 abr 2026 · NCT05683418First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Renown Regional Medical Center, Reno
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2025 · NCT05216432De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.